Assessment of Platelet-derived GARP in Atherosclerotic Disease

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversité Catholique de Louvain

About this trial

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Eligibility criteria

Qualifiers

Older than 18 years

Able to give informed consent

Undergoing carotid or femoral endarterectomy

Disqualifiers

Younger than 18 years

Pregnant

Dialysis

Unable to give informed consent

Trial design

Treatments tested in this trial

  • Tissue sample and data collection

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Université Catholique de Louvain

Lead sponsor

Fonds National de la Recherche Scientifique

Collaborator